NCT03480568Unknown3 期
A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Change in LDL cholesterol levels
研究概览
简要总结
12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.
详细描述
Primary objective: The objective of this trial is to demonstrate the efficacy of alirocumab 150 mg every 2 weeks over 12 weeks on cholesterol levels.
Secondary objective: To assess the safety of treating chronic dialysis patients with alirocumab 150 mg subcutaneously every 2 weeks for 12 weeks.
Secondary objective: To demonstrate the efficacy of alirocumab 150 mg every 2 weeks over 12 weeks on biomarkers.
Exploratory objective: To assess alirocumab drug levels in subjects maintained on hemodialysis and peritoneal dialysis.
Methodology: Open-label, nonrandomized study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, ages 18 to 80 years.
- •Written informed consent will be obtained before any study assessment is performed.
- •Diagnosis of end-stage renal disease, maintained on dialysis, without dialysis complications, for at least 3 months.
- •Patients may or may not have a diagnosis of atherosclerotic disease, such as a history of myocardial infarction (MI), cardiac percutaneous coronary intervention (PCI), coronary artery bypass (CABG) surgery, atherosclerotic transient ischemic attack (TIA) or cerebrovascular attack (CVA), or peripheral arterial disease (PAD).
- •A total of 20 patients will be enrolled, 10 patients on hemodialysis and 10 patients on peritoneal dialysis.
排除标准
- •LDL-cholesterol level of < 70 mg/dL.
- •Any contraindication to subcutaneous injections.
- •Patients on statin and/or ezetimibe therapy will have their cholesterol-lowering therapy continued as is without change during the time of the study.
- •History of any allergy or intolerance to the study drug or drugs of the same class.
- •A history of MI, PCI, CABG surgery, TIA, CVA, or PAD events within 3 months of enrollment.
- •History of malignant cancer within the past 3 years, excepting basal cell skin cancer or cervical cancer in situ.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of the drug and for 2 weeks after the last injection of the drug. Highly effective methods of contraception include:
- •Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment.
- •Male sterilization (at least 6 months prior to enrollment). For female patients in the study, the vasectomized male partner should be the sole partner for that patient.
- •Use of oral (estrogen and/or progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception.
- •In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
- •Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before enrollment.
- •Pregnant or lactating women.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or extraction of study drug, at investigator's discretion.
- •History or evidence of drug or alcohol abuse within the last 12 months.
- •Patients considered unsuitable for the study, including patients with psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.
研究组 & 干预措施
alirocumab
Experimental
Alirocumab 150 mg q 2 weeks for 12 weeks
干预措施: Alirocumab 150 MG/ML [Praluent] (Drug)
结局指标
主要结局
Change in LDL cholesterol levels
时间窗: Baseline, 4 ,8, 12 weeks
Efficacy
次要结局
- Change in HDL-cholesterol levels(Baseline, 12 weeks)
- Change in apoprotein B levels(Baseline, 4, 8, 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis PatientsSecondary HyperparathyroidismEnd Stage Renal DiseaseNCT00037635Amgen400
已完成
3 期
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)Plaque PsoriasisNCT01729754Sun Pharmaceutical Industries Limited1,090
招募中
不适用
RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)End Stage Renal Disease on DialysisNCT04360694Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari190
已完成
1 期
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal DiseaseAnemia in Chronic Kidney DiseaseNCT01978587Akros Pharma Inc.6
已完成
3 期
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)AnaemiaNCT03400033GlaxoSmithKline407